ibrutinib,rituximab
abbvie,janssen
[' ibru', 'mantle,(-dismantle)', ' aca ', 'lymphoma']
outcomes in a+i were superior to a alone and it s not clear that a+i was superior to i alone as maintenance for mcl and toxicity is less with i alone. this looks like it favors ibrutinib as consolidation for mantle cell lymphoma. #ash22 plenary session. 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.